Bli medlem
Bli medlem

Du är här

2014-03-25

Aerocrine: Change in number of shares and votes in Aerocrine

With reference to Chapter 4 Section 9 in "lagen (1991:980) om handel
med finansiella instrument" it's hereby announced that through the
subscription by a new share issue in Aerocrine the number of shares
and votes in Aerocrine has increased during March 2013 as specified
in the table below.

Number of shares and votes
March 1, 2014 154 628 698
Increase 222 496
March 31, 2014 154 851 194

Solna March 31, 2014

Aerocrine AB (publ.)

For further information, please contact:

Michael Colérus, CFO, +46 8 629 07 85

About Aerocrine

Aerocrine AB is a medical products company focused on improved
management and care of patients with inflammatory airway diseases
such as Asthma. Within this sector, Aerocrine is the world leader.
Aerocrine markets NIOX MINO® and NIOX VERO®, which enables fast and
reliable point-of-care measurement of airway inflammation. These
products plays a critical role in more effective diagnosis, treatment
and follow-up of patients affected with inflammatory airway diseases.
Aerocrine is based in Sweden with subsidiaries in the US, Germany,
Switzerland and the UK. Aerocrine shares have been listed on the
Stockholm Stock Exchange since 2007 (AERO-B.ST). For more information
please visit www.aerocrine.com and www.niox.com.

+------------------------------------------------------------------------------+
|Aerocrine may be required to disclose the information provided herein pursuant|
|to the Securities Markets Act and/or the Financial Instruments Trading Act. |
|The information was submitted for publication at 08:00 am on March 31, 2014. |
+------------------------------------------------------------------------------+

-----------------------------------------------------------
http://news.cision.com/aerocrine/r/change-in-number-of-shares-and-votes-...
http://mb.cision.com/Main/49/9557715/224819.pdf

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.